## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person* VANCE DOLLY  (Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC.,, 1180 VETERANS BLVD.  (Street)				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
				Date of Earliest Transaction (Month/Day/Year)     05/10/2005      4. If Amendment, Date Original Filed(Month/Day/Year)							X_Of						
											6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City)		(State)	(Zip)														
		(23)		1		_	1				-	_	•		ially Owned		
(Instr. 3) Da		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Followi Transaction(s)		ecurities Beneficially ng Reported		6. Ownership Form:	Beneficial		
				(Montr	и⊅ау	// Y ear	Code	e V	Amoun	(A) or (D)	Price	or In (I)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common S	Stock		05/10/2005				M		15,000	) A	\$ 9.2	19,38	5			D	
Common S	Stock		05/10/2005			S	1:	15,000	)11) 1	\$ 19.71	4,385	85		D	)		
Reminder, Re	•	parate line for each c	class of securities ber	neficially	own /	ned din	ectly or ir	Perso	orm are	not req	uired 1		nd unles		contained displays a	in SEC	1474 (9-02
Teaminger. Re	•	parate line for each c		- Deriva	ntive :	Secur	ities Acqı	Perso this f curre uired, Dis	orm are ntly val	not required in the not required in the notice in the noti	uired to contro ficially	to respoi ol numbe	nd unles			in SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date		- Deriva (e.g., p 4. Transact Code	uts, c	Secur calls, v 5. Nu of De Secur Acqui or Dis of (D) (Instr.	ities Acquerrants, mber 6 rivative E tities (I) posed 3, 4,	Perso this f curre	orm are ntly val posed o converti ercisable Date	e not req lid OMB f, or Bene ible secur	of Se	to respoi ol numbe	nd unles r. Amount		9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Owners Form o Derivat Security Direct ( or Indir	11. Nathing of India Benefit Owner: (Instr. 4
Title of     Derivative     Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II  3A. Deemed Execution Date, if any	- Deriva (e.g., p 4. Transact Code	uts, c	Secur 5. Nu of De Secur Acqui or Dis of (D) (Instr.	ities Acquestrants, mber 6 rivative Etities (I) posed 3, 4,	Perso this fo curre uired, Dis options, 5. Date Ex Expiration	orm are ntly val	e not req lid OMB f, or Bene ible secur	ontro	to respondent to	nd unles r. Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	f 10. Owners Form o Derivat Security Direct ( or Indir	11. Na of Indi Benefi Owner (Instr.

			Relationships	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
VANCE DOLLY RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			VP Intel. Prop.& Gen.Counsel	

## **Signatures**

/s/Dolly Vance	05/10/2005
**Signature of Reporting Person	Date

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests 20% at 6 month anniversary from 7/28/03, 20% on at 1 year anniversary from 7/28/03 and the remaining 60% vests monthly over twenty-four (24) months from 7/28/04.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.